For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on fractures but an increased risk for major adverse cardiovascular events (MACE) ...
Ospomyv and Xbryk, biosimilars to Prolia and Xgeva, received FDA approval for osteoporosis and bone loss treatment. Clinical studies confirmed equivalent efficacy, safety, and pharmacokinetics between ...
Researchers performed a retrospective chart review and survey of 107 patients to compare the efficacy, patient satisfaction, cost and known adverse effects of denosumab versus zoledronic acid, ...
Please provide your email address to receive an email when new articles are posted on . Compared with oral bisphosphonate use, denosumab use was associated with a 45% lower risk for fractures among ...
THOUSAND OAKS, Calif., Sept. 8, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that 19 scientific abstracts will highlight the latest scientific research on EVENITY™* (romosozumab) and ...
LOS ANGELES, May 28 (Reuters) - Amgen Inc said on Wednesday its experimental osteoporosis drug denosumab achieved greater bone density than Merck & Co Inc's Fosamax, but some analysts expressed ...
Stoboclo and Osenvelt, biosimilars of Prolia and Xgeva, are approved for various cancer-related bone conditions, offering cost-effective alternatives. FDA approval confirms therapeutic equivalence of ...
The study included 1032 patients: 658 denosumab users and 374 oral bisphosphonate users. HealthDay News — For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results